Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6VD4L)

Drug Name

KZR-616 Drug Info

Synonyms

Zetomipzomib; KZR-616; 1629677-75-3; UNII-O4BT6C02M2; O4BT6C02M2; (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide; D-Erythro-3-pentulose, 4,5-anhydro-1-(1-cyclopenten-1-yl)-1,2-dideoxy-4-C-methyl-2-((N-(2-(4-morpholinyl)acetyl)-L-alanyl-(betaR)-beta-hydroxy-O-methyl-L-tyrosyl)amino)-; D-erythro-3-Pentulose, 4,5-anhydro-1-(1-cyclopenten-1-yl)-1,2-dideoxy-4-C-methyl-2-[[N-[2-(4-morpholinyl)acetyl]-L-alanyl-(betaR)-beta-hydroxy-O-methyl-L-tyrosyl]amino]-; ZETOMIPZOMIB [INN]; ZETOMIPZOMIB [USAN]; KZR616; CHEMBL4297468; SCHEMBL16118957; GTPL10409; EX-A6921; BDBM50526811; AKOS040755812; compound 12 [PMID: 30380863]; HY-114419; CS-0085023; (2S,3R)-N-((S)-3-(cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide; (2S,3R)N((S)3-(Cyclopent-1-en-1-yl)-1-((R)2-methyloxiran-2-yl)-1- oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)2-(2- morpholinoacetamido)propanamido)propenamide; 4,5-ANHYDRO-1-(1-CYCLOPENTEN-1-YL)-1,2-DIDEOXY-4-C-METHYL-2-((N-(2-(4-MORPHOLINYL)ACETYL)-L-ALANYL-(.BETA.R)-.BETA.-HYDROXY-O-METHYL-L-TYROSYL)AMINO)-D-ERYTHRO-3-PENTULOSE; 4,5-Anhydro-1-(1-cyclopenten-1-yl)-1,2-dideoxy-4-C-methyl-2-((N-(2-(4-morpholinyl)acetyl)-L-alanyl-(betaR)-beta-hydroxy-O-methyl-L-tyrosyl)amino)-D-erythro-3-pentulose

Indication

Disease Entry	ICD 11	Status	REF
Dermatomyositis	4A41.0	Phase 2	[1]
Polymyositis	4A41.1	Phase 2	[1]

Cross-matching ID

PubChem CID: 117607904
TTD Drug ID: DM6VD4L

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Immunoproteasome complex (IP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Peptide analog 10	DMYKOAM	N. A.	N. A.	Patented	[3]
Peptide analog 40	DM12VO9	N. A.	N. A.	Patented	[3]
PMID29865878-Compound-41	DMSAO52	N. A.	N. A.	Patented	[3]
PMID29865878-Compound-38	DMCZ3SH	N. A.	N. A.	Patented	[3]
Peptide analog 30	DMYEJV0	N. A.	N. A.	Patented	[3]
Peptide analog 16	DMKJ27D	N. A.	N. A.	Patented	[3]
Peptide analog 26	DM8FGZB	N. A.	N. A.	Patented	[3]
Peptide analog 24	DM904T7	N. A.	N. A.	Patented	[3]
PMID29865878-Compound-54	DMED71P	N. A.	N. A.	Patented	[3]
PMID29865878-Compound-56	DM45QW1	N. A.	N. A.	Patented	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Immunoproteasome complex (IP)	TTSJMN8	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04628936) An Open-label Extension to the Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis. U.S.National Institutes of Health.
2	Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses. Front Immunol. 2023 Mar 10;14:1043680.
3	A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540.